The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

24 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Structural and Thermodynamic Characterization of Protein-Ligand Interactions Formed between Lipoprotein-Associated Phospholipase A2 and Inhibitors.EBI
Shanghaitech University
Transformation of a Dopamine DEBI
Shanghaitech University
Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2.EBI
Shanghaitech University
2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design.EBI
Shanghaitech University
Structure-Based Ligand Discovery Targeting the Transmembrane Domain of Frizzled Receptor FZD7.EBI
Shanghaitech University
Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group.EBI
Shanghaitech University
Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.EBI
Shanghaitech University
Dual-acting antitumor agents targeting the AEBI
Shanghaitech University
Synthesis and pharmacological validation of fluorescent diarylsulfonylurea analogues as NLRP3 inhibitors and imaging probes.EBI
Shanghaitech University
Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.EBI
Shanghaitech University
Rational Remodeling of Atypical Scaffolds for the Design of Photoswitchable Cannabinoid Receptor Tools.EBI
Shanghaitech University
Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.EBI
Shanghaitech University
Structure-Based Design of Dual-Acting Compounds Targeting Adenosine AEBI
Shanghaitech University
2-Phenylcyclopropylmethylamine Derivatives as Dopamine DEBI
Shanghaitech University
Elucidation of Distinct Modular Assemblies of Smoothened Receptor by Bitopic Ligand Measurement.EBI
Shanghaitech University
Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.EBI
Shanghaitech University
Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.EBI
Shanghaitech University
Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.EBI
Shanghaitech University
Colocalization Strategy Unveils an Underside Binding Site in the Transmembrane Domain of Smoothened Receptor.EBI
Shanghaitech University
Design and Synthesis of Bitopic 2-Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands.EBI
Shanghaitech University
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.EBI
Shanghaitech University
Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.EBI
Shanghaitech University
HETEROAROMATIC COMPOUNDSBDB
Astrazeneca
Inhibition of human caspases by peptide-based and macromolecular inhibitors.BDB
Merck Research Laboratories